Actively Recruiting
Safety and Early Effectiveness Study of STUP-001 Gene Therapy for Adults with Chronic Spinal Cord Injury AIS-A or B
Led by Yonsei University · Updated on 2025-07-16
9
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and exploratory effectiveness of STUP-001, an investigational gene therapy for adults aged 19 to 60 with chronic traumatic spinal cord injury classified as AIS-A or B. This therapy aims to convert certain spinal cord cells into functional neurons, potentially improving motor function. The trial is a single-center, prospective study led by Dr. Junsang Yoo and sponsored by Yonsei University. Participants receive STUP-001 as an injection directly into the spinal cord through an intraparenchymal route. Two dosing groups exist one receiving 25 microliters and another receiving 50 microliters of the gene therapy. The study includes a screening phase followed by a 7-month evaluation period to monitor safety, tolerability, and early signs of effectiveness. During the study, participants will be closely observed for dose-limiting toxicity within 4 weeks after receiving the gene therapy. Researchers will assess safety and exploratory efficacy through various evaluations over the 7 months. Participants must be able to consent and comply with study procedures, and safety will be monitored throughout with follow-up visits to track responses and any adverse effects.
CONDITIONS
Brief Title
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
Research Team
J
Junsang Yoo, Ph D.
C
Chunggu Kim, Ph D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here